IFP Advisors
PRME icon

IFP Advisors’s Prime Medicine PRME Stock Holding History

IFP Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85 Buy
23
+21
+1,050% +$70 ﹤0.01% 4977
2026
Q1 		$7 Sell
2
-8
-80% -$30 ﹤0.01% 4983
2025
Q4 		$35 Buy
10
+1
+11% +$4 ﹤0.01% 4745
2025
Q3 		$50 Buy
9
+1
+13% +$4 ﹤0.01% 4658
2025
Q2 		$20 Sell
8
-16
-67% -$25 ﹤0.01% 4846
2025
Q1 		$48 Hold
24
– – ﹤0.01% 4031
2024
Q4 		$70 Buy
+24
New +$84 ﹤0.01% 4153

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

IFP Advisors's PRME Position: Q2 2026 in Review

IFP Advisors increased its Prime Medicine (PRME) stake by 1,050% in Q2 2026, buying an estimated $70 and bringing the position to 23 shares worth $85. The position accounts for ﹤0.01% of the portfolio, ranked #4977.

IFP Advisors first reported a position in PRME in Q4 2024 and has held it in 7 quarters since. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • IFP Advisors held 23 shares of Prime Medicine worth $85 as of Q2 2026.
  • IFP Advisors bought 21 Prime Medicine shares in Q2 2026, an estimated $70.
  • Prime Medicine made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4977 holding.
  • IFP Advisors first reported a position in Prime Medicine in Q4 2024 and has held it in 7 quarters since.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.